Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE versus KEFZOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE versus KEFZOL.
CEFEPIME HYDROCHLORIDE vs KEFZOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase and carboxypeptidase activity, leading to cell lysis.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
1-2 g IV every 8-12 hours; for uncomplicated urinary tract infections, 500 mg IV every 12 hours.
1-2 g IV/IM every 8 hours for moderate to severe infections; maximum 12 g/day.
None Documented
None Documented
2-2.3 hours in healthy adults (prolonged to 13-15 hours in severe renal impairment; requires dosage adjustment).
1.5-2 hours in adults with normal renal function; prolonged to 20-30 hours in end-stage renal disease (CrCl <10 mL/min).
Primarily renal (≈85% unchanged via glomerular filtration and tubular secretion); biliary/fecal <1%.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: minimal (<5%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic